Search

Your search keyword '"Dinardo, Courtney D."' showing total 3,027 results
Start Over Author "Dinardo, Courtney D."
3,027 results on '"Dinardo, Courtney D."'

151. Oral decitabine–cedazuridine in acute myeloid leukaemia.

Author

Bouligny, Ian M. and DiNardo, Courtney D.

Subjects
*ACUTE myeloid leukemia, *DECITABINE, *PHARMACOKINETICS, *PHARMACODYNAMICS, *CANCER chemotherapy
Abstract

In a randomized crossover study involving 89 patients with acute myeloid leukaemia ineligible for intensive chemotherapy, Geissler et al. compared intravenous decitabine and oral decitabine–cedazuridine. The pharmacokinetics and pharmacodynamics of the two formulations were similar. The clinical efficacy of oral decitabine–cedazuridine was consistent with historical data of intravenous decitabine. Commentary on: Geissler et al. Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. Br J Haematol 2024; 205:1734‐1745. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

155. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

Author

DiNardo, Courtney D, Pratz, Keith W, Letai, Anthony, Jonas, Brian A, Wei, Andrew H, Thirman, Michael, Arellano, Martha, Frattini, Mark G, Kantarjian, Hagop, Popovic, Relja, Chyla, Brenda, Xu, Tu, Dunbar, Martin, Agarwal, Suresh K, Humerickhouse, Rod, Mabry, Mack, Potluri, Jalaja, Konopleva, Marina, and Pollyea, Daniel A

Published
2018
Full Text
View/download PDF

156. Data from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Author

Senapati, Jayastu, primary, Fiskus, Warren C., primary, Daver, Naval, primary, Wilson, Nathaniel R., primary, Ravandi, Farhad, primary, Garcia-Manero, Guillermo, primary, Kadia, Tapan, primary, DiNardo, Courtney D., primary, Jabbour, Elias, primary, Burger, Jan, primary, Short, Nicholas J., primary, Alvarado, Yesid, primary, Jain, Nitin, primary, Masarova, Lucia, primary, Issa, Ghayas C., primary, Qiao, Wei, primary, Khoury, Joseph D., primary, Pierce, Sherry, primary, Miller, Darla, primary, Sasaki, Koji, primary, Konopleva, Marina, primary, Bhalla, Kapil N., primary, Borthakur, Gautam, primary, and Pemmaraju, Naveen, primary

Published
2023
Full Text
View/download PDF

157. Clinical Trial Protocol S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Author

Senapati, Jayastu, primary, Fiskus, Warren C., primary, Daver, Naval, primary, Wilson, Nathaniel R., primary, Ravandi, Farhad, primary, Garcia-Manero, Guillermo, primary, Kadia, Tapan, primary, DiNardo, Courtney D., primary, Jabbour, Elias, primary, Burger, Jan, primary, Short, Nicholas J., primary, Alvarado, Yesid, primary, Jain, Nitin, primary, Masarova, Lucia, primary, Issa, Ghayas C., primary, Qiao, Wei, primary, Khoury, Joseph D., primary, Pierce, Sherry, primary, Miller, Darla, primary, Sasaki, Koji, primary, Konopleva, Marina, primary, Bhalla, Kapil N., primary, Borthakur, Gautam, primary, and Pemmaraju, Naveen, primary

Published
2023
Full Text
View/download PDF

158. Supplementary Table S2 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Author

Senapati, Jayastu, primary, Fiskus, Warren C., primary, Daver, Naval, primary, Wilson, Nathaniel R., primary, Ravandi, Farhad, primary, Garcia-Manero, Guillermo, primary, Kadia, Tapan, primary, DiNardo, Courtney D., primary, Jabbour, Elias, primary, Burger, Jan, primary, Short, Nicholas J., primary, Alvarado, Yesid, primary, Jain, Nitin, primary, Masarova, Lucia, primary, Issa, Ghayas C., primary, Qiao, Wei, primary, Khoury, Joseph D., primary, Pierce, Sherry, primary, Miller, Darla, primary, Sasaki, Koji, primary, Konopleva, Marina, primary, Bhalla, Kapil N., primary, Borthakur, Gautam, primary, and Pemmaraju, Naveen, primary

Published
2023
Full Text
View/download PDF

159. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor

Author

Fiskus, Warren C, primary, Piel, Jessica, additional, Collins, Mike, additional, Hentemann, Murphy, additional, Cuglievan, Branko, additional, Mill, Christopher P, additional, Birdwell, Christine E, additional, Das, Kaberi, additional, Davis, John A, additional, Hou, Hanxi, additional, Jain, Antrix C, additional, Malovannaya, Anna, additional, Kadia, Tapan M, additional, Daver, Naval, additional, Sasaki, Koji, additional, Takahashi, Koichi, additional, Hammond, Danielle, additional, Reville, Patrick K, additional, Wang, Jian, additional, Loghavi, Sanam, additional, Sen, Rwik, additional, Ruan, Xinjia, additional, Su, Xiaoping, additional, Flores, Lauren B, additional, DiNardo, Courtney D, additional, and Bhalla, Kapil N, additional

Published
2023
Full Text
View/download PDF

160. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants

Author

Bataller, Alex, primary, Loghavi, Sanam, additional, Gerstein, Yoheved, additional, Bazinet, Alexandre, additional, Sasaki, Koji, additional, Chien, Kelly S., additional, Hammond, Danielle, additional, Montalban‐Bravo, Guillermo, additional, Borthakur, Gautam, additional, Short, Nicholas, additional, Issa, Ghayas C., additional, Kadia, Tapan M., additional, Daver, Naval, additional, Tang, Guilin, additional, Quesada, Andres, additional, Patel, Keyur P., additional, Ravandi, Farhad, additional, Fiskus, Warren, additional, Mill, Cristopher P., additional, Kantarjian, Hagop M., additional, Bhalla, Kapil, additional, Garcia‐Manero, Guillermo, additional, Oran, Betul, additional, and DiNardo, Courtney D., additional

Published
2023
Full Text
View/download PDF

161. AML-207 Characteristics and Outcomes of Patients With Acute Myeloid Leukemia and DDX41 Mutation

Author

Bataller, Alex, primary, Loghavi, Sanam, additional, Gerstein, Yoheved, additional, Bazinet, Alexandre, additional, Sasaki, Koji, additional, Chien, Kelly S., additional, Hammond, Danielle, additional, Montalban-Bravo, Guillermo, additional, Borthakur, Gautam, additional, Short, Nicholas, additional, Issa, Ghayas C, additional, Kadia, Tapan M, additional, Daver, Naval, additional, Patel, Keyur P, additional, Ravandi, Farhad, additional, Fiskus, Warren, additional, Mill, Cristopher P, additional, Kantarjian, Hagop M, additional, Bhalla, Kapil, additional, Garcia-Manero, Guillermo, additional, Oran, Betul, additional, and DiNardo, Courtney D, additional

Published
2023
Full Text
View/download PDF

162. POSTER: MDS-457 Ivosidenib in Mutant IDH1 Relapsed/Refractory Myelodysplastic Syndrome: Updated Substudy Results

Author

DiNardo, Courtney D., primary, Roboz, Gail J., additional, Watts, Justin M., additional, Madanat, Yazan F., additional, Prince, Gabrielle T., additional, Baratam, Praneeth, additional, de Botton, Stéphane, additional, Stein, Anthony, additional, Foran, James M., additional, Arellano, Martha L., additional, Sallman, David A., additional, Marchione, Dylan M., additional, Bai, Xiaofei, additional, Patel, Prapti A., additional, Kapsalis, Stephanie M., additional, Garcia-Manero, Guillermo, additional, and Fathi, Amir T., additional

Published
2023
Full Text
View/download PDF

163. MDS-208 Characteristics and Outcomes of Patients With Myelodysplastic Syndrome and DDX41 Mutation

Author

Bataller, Alex, primary, Loghavi, Sanam, additional, Gerstein, Yoheved, additional, Bazinet, Alexandre, additional, Sasaki, Koji, additional, Chien, Kelly S., additional, Hammond, Danielle, additional, Montalban-Bravo, Guillermo, additional, Borthakur, Gautam, additional, Short, Nicholas, additional, Issa, Ghayas C, additional, Kadia, Tapan M, additional, Daver, Naval, additional, Patel, Keyur P, additional, Ravandi, Farhad, additional, Fiskus, Warren, additional, Mill, Cristopher P, additional, Kantarjian, Hagop M, additional, Bhalla, Kapil, additional, Garcia-Manero, Guillermo, additional, Oran, Betul, additional, and DiNardo, Courtney D, additional

Published
2023
Full Text
View/download PDF

164. POSTER: MDS-208 Characteristics and Outcomes of Patients With Myelodysplastic Syndrome and DDX41 Mutation

Author

Bataller, Alex, primary, Loghavi, Sanam, additional, Gerstein, Yoheved, additional, Bazinet, Alexandre, additional, Sasaki, Koji, additional, Chien, Kelly S., additional, Hammond, Danielle, additional, Montalban-Bravo, Guillermo, additional, Borthakur, Gautam, additional, Short, Nicholas, additional, Issa, Ghayas C, additional, Kadia, Tapan M, additional, Daver, Naval, additional, Patel, Keyur P, additional, Ravandi, Farhad, additional, Fiskus, Warren, additional, Mill, Cristopher P, additional, Kantarjian, Hagop M, additional, Bhalla, Kapil, additional, Garcia-Manero, Guillermo, additional, Oran, Betul, additional, and DiNardo, Courtney D, additional

Published
2023
Full Text
View/download PDF

165. MDS-457 Ivosidenib in Mutant IDH1 Relapsed/Refractory Myelodysplastic Syndrome: Updated Substudy Results

Author

DiNardo, Courtney D., primary, Roboz, Gail J., additional, Watts, Justin M., additional, Madanat, Yazan F., additional, Prince, Gabrielle T., additional, Baratam, Praneeth, additional, de Botton, Stéphane, additional, Stein, Anthony, additional, Foran, James M., additional, Arellano, Martha L., additional, Sallman, David A., additional, Marchione, Dylan M., additional, Bai, Xiaofei, additional, Patel, Prapti A., additional, Kapsalis, Stephanie M., additional, Garcia-Manero, Guillermo, additional, and Fathi, Amir T., additional

Published
2023
Full Text
View/download PDF

166. POSTER: AML-207 Characteristics and Outcomes of Patients With Acute Myeloid Leukemia and DDX41 Mutation

Author

Bataller, Alex, primary, Loghavi, Sanam, additional, Gerstein, Yoheved, additional, Bazinet, Alexandre, additional, Sasaki, Koji, additional, Chien, Kelly S., additional, Hammond, Danielle, additional, Montalban-Bravo, Guillermo, additional, Borthakur, Gautam, additional, Short, Nicholas, additional, Issa, Ghayas C, additional, Kadia, Tapan M, additional, Daver, Naval, additional, Patel, Keyur P, additional, Ravandi, Farhad, additional, Fiskus, Warren, additional, Mill, Cristopher P, additional, Kantarjian, Hagop M, additional, Bhalla, Kapil, additional, Garcia-Manero, Guillermo, additional, Oran, Betul, additional, and DiNardo, Courtney D, additional

Published
2023
Full Text
View/download PDF

167. Final phase 1 substudy results of ivosidenib for patients with mutant IDH1relapsed/refractory myelodysplastic syndrome

Author

DiNardo, Courtney D., Roboz, Gail J., Watts, Justin M., Madanat, Yazan F., Prince, Gabrielle T., Baratam, Praneeth, de Botton, Stéphane, Stein, Anthony, Foran, James M., Arellano, Martha L., Sallman, David A., Hossain, Mohammad, Marchione, Dylan M., Bai, Xiaofei, Patel, Prapti A., Kapsalis, Stephanie M., Garcia-Manero, Guillermo, and Fathi, Amir T.

Abstract

•Ivosidenib resulted in a CR rate of 38.9% and an OR rate of 83.3% in mIDH1R/R MDS; median duration of response was not reached.•Median OS in this R/R MDS cohort was ∼36 months; ∼75% of RBC- and platelet-transfusion–dependent patients became transfusion independent.

Published
2024
Full Text
View/download PDF

168. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Author

Maiti, Abhishek, DiNardo, Courtney D., Daver, Naval G., Rausch, Caitlin R., Ravandi, Farhad, Kadia, Tapan M., Pemmaraju, Naveen, Borthakur, Gautam, Bose, Prithviraj, Issa, Ghayas C., Short, Nicholas J., Yilmaz, Musa, Montalban-Bravo, Guillermo, Ferrajoli, Alessandra, Jabbour, Elias J., Jain, Nitin, Ohanian, Maro, Takahashi, Koichi, Thompson, Philip A., Loghavi, Sanam, Montalbano, Kathryn S., Pierce, Sherry, Wierda, William G., Kantarjian, Hagop M., and Konopleva, Marina Y.

Published
2021
Full Text
View/download PDF

169. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Author

Stein, Eytan M., DiNardo, Courtney D., Pollyea, Daniel A., Fathi, Amir T., Roboz, Gail J., Altman, Jessica K., Stone, Richard M., DeAngelo, Daniel J., Levine, Ross L., Flinn, Ian W., Kantarjian, Hagop M., Collins, Robert, Patel, Manish R., Frankel, Arthur E., Stein, Anthony, Sekeres, Mikkael A., Swords, Ronan T., Medeiros, Bruno C., Willekens, Christophe, Vyas, Paresh, Tosolini, Alessandra, Xu, Qiang, Knight, Robert D., Yen, Katharine E., Agresta, Sam, de Botton, Stephane, and Tallman, Martin S.

Published
2017
Full Text
View/download PDF

172. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

Author

Yilmaz, Musa, Alfayez, Mansour, DiNardo, Courtney D., Borthakur, Gautam, Kadia, Tapan M., Konopleva, Marina Y., Loghavi, Sanam, Kanagal-Shamanna, Rashmi, Patel, Keyur P., Jabbour, Elias J., Garcia-Manero, Guillermo, Pemmaraju, Naveen, Pierce, Sherry A., Ghayas, Issa, Short, Nicholas J., Montalban-Bravo, Guillermo, Takahashi, Koichi, Assi, Rita, Alotaibi, Ahmad S., Ohanian, Maro, Andreeff, Michael, Cortes, Jorge E., Kantarjian, Hagop M., Ravandi, Farhad, and Daver, Naval G.

Published
2020
Full Text
View/download PDF

173. Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Author

Morita, Kiyomi, Wang, Feng, Jahn, Katharina, Hu, Tianyuan, Tanaka, Tomoyuki, Sasaki, Yuya, Kuipers, Jack, Loghavi, Sanam, Wang, Sa A., Yan, Yuanqing, Furudate, Ken, Matthews, Jairo, Little, Latasha, Gumbs, Curtis, Zhang, Jianhua, Song, Xingzhi, Thompson, Erika, Patel, Keyur P., Bueso-Ramos, Carlos E., DiNardo, Courtney D., Ravandi, Farhad, Jabbour, Elias, Andreeff, Michael, Cortes, Jorge, Bhalla, Kapil, Garcia-Manero, Guillermo, Kantarjian, Hagop, Konopleva, Marina, Nakada, Daisuke, Navin, Nicholas, Beerenwinkel, Niko, Futreal, P. Andrew, and Takahashi, Koichi

Published
2020
Full Text
View/download PDF

174. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Author

Morita, Kiyomi, Wang, Feng, Jahn, Katharina, Hu, Tianyuan, Tanaka, Tomoyuki, Sasaki, Yuya, Kuipers, Jack, Loghavi, Sanam, Wang, Sa A., Yan, Yuanqing, Furudate, Ken, Matthews, Jairo, Little, Latasha, Gumbs, Curtis, Zhang, Jianhua, Song, Xingzhi, Thompson, Erika, Patel, Keyur P., Bueso-Ramos, Carlos E., DiNardo, Courtney D., Ravandi, Farhad, Jabbour, Elias, Andreeff, Michael, Cortes, Jorge, Bhalla, Kapil, Garcia-Manero, Guillermo, Kantarjian, Hagop, Konopleva, Marina, Nakada, Daisuke, Navin, Nicholas, Beerenwinkel, Niko, Futreal, P. Andrew, and Takahashi, Koichi

Published
2020
Full Text
View/download PDF

177. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3 -Mutated AML.

Author

Short, Nicholas J., Daver, Naval, Dinardo, Courtney D., Kadia, Tapan, Nasr, Lewis F., Macaron, Walid, Yilmaz, Musa, Borthakur, Gautam, Montalban-Bravo, Guillermo, Garcia-Manero, Guillermo, Issa, Ghayas C., Chien, Kelly S., Jabbour, Elias, Nasnas, Cedric, Huang, Xuelin, Qiao, Wei, Matthews, Jairo, Stojanik, Christopher J., Patel, Keyur P., and Abramova, Regina

Published
2024
Full Text
View/download PDF

178. Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.

Author

Jen, Wei-Ying, Sasaki, Koji, Rausch, Caitlin R., DiNardo, Courtney D., Kadia, Tapan M., Yilmaz, Musa, Borthakur, Gautam, Alvarado, Yesid, McCue, David, McCue, Deborah, Kantarjian, Hagop M., and Ravandi, Farhad

Subjects
ACUTE promyelocytic leukemia, ACUTE kidney failure, ARSENIC trioxide, OBESITY, MULTIVARIATE analysis
Abstract

Arsenic trioxide (ATO)-based regimens are standard in acute promyelocytic leukemia (APL). ATO-related nephrotoxicity has not been reported. We reviewed APL patients treated with ATO to identify cases of acute kidney injury (AKI). Clinically significant cases were characterized. Multivariate analysis was performed to identify predictors of idiopathic, clinically significant AKI. One hundred and eight patients were included. ATO dose was 0.15 mg/kg/day using actual body weight with no dose cap. Thirty-one (28.7%) AKI cases were identified, 10 (32.3%) clinically significant. Six were idiopathic; five required dialysis. The proportion with significant, idiopathic AKI was 15.8% in patients receiving >15mg ATO versus 0% in those receiving ≤15mg (p = 0.001). On multivariate analysis, only ATO dose was a significant predictor of clinically significant AKI (odds ratio of 1.91, 95%CI, 1.19–3.07, p = 0.007). High-dose ATO may be associated with significant nephrotoxicity. We recommend that ATO dose be capped at 15 mg to minimize toxicity for this curable disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

181. Understanding the evolving phenotype of vascular complications in telomere biology disorders

Author

Higgs, Cecilia, Crow, Yanick J., Adams, Denise M., Chang, Emmanuel, Hayes, Jr., Don, Herbig, Utz, Huang, James N., Himes, Ryan, Jajoo, Kunal, Johnson, F. Brad, Reynolds, Susan D., Yonekawa, Yoshihiro, Armanios, Mary, Boulad, Farid, DiNardo, Courtney D., Dufour, Carlo, Goldman, Frederick D., Khan, Shakila, Kratz, Christian, Myers, Kasiani C., Raghu, Ganesh, Alter, Blanche P., Aubert, Geraldine, Bhala, Sonia, Cowen, Edward W., Dror, Yigal, El-Youssef, Mounif, Friedman, Bruce, Giri, Neelam, Helms Guba, Lisa, Khincha, Payal P., Lin, Tiffany F., Longhurst, Hilary, McReynolds, Lisa J., Nelson, Adam, Olson, Tim, Pariser, Anne, Perona, Rosario, Sasa, Ghadir, Schratz, Kristen, Simonetto, Douglas A., Townsley, Danielle, Walsh, Michael, Stevens, Katherine, Agarwal, Suneet, Bertuch, Alison A., Savage, Sharon A., and the Clinical Care Consortium for Telomere-associated Ailments (CCCTAA)

Published
2019
Full Text
View/download PDF

182. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies

Author

Bataller, Alex, primary, Abuasab, Tareq, additional, McCall, David, additional, Wang, Wei, additional, Cuglievan, Branko, additional, Issa, Ghayas C., additional, Jabbour, Elias, additional, Short, Nicholas, additional, DiNardo, Courtney D., additional, Tang, Guilin, additional, Garcia-Manero, Guillermo, additional, Kantarjian, Hagop M., additional, and Sasaki, Koji, additional

Published
2023
Full Text
View/download PDF

183. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Author

Senapati, Jayastu, primary, Fiskus, Warren C., additional, Daver, Naval, additional, Wilson, Nathaniel R., additional, Ravandi, Farhad, additional, Garcia-Manero, Guillermo, additional, Kadia, Tapan, additional, DiNardo, Courtney D., additional, Jabbour, Elias, additional, Burger, Jan, additional, Short, Nicholas J., additional, Alvarado, Yesid, additional, Jain, Nitin, additional, Masarova, Lucia, additional, Issa, Ghayas C., additional, Qiao, Wei, additional, Khoury, Joseph D., additional, Pierce, Sherry, additional, Miller, Darla, additional, Sasaki, Koji, additional, Konopleva, Marina, additional, Bhalla, Kapil N., additional, Borthakur, Gautam, additional, and Pemmaraju, Naveen, additional

Published
2023
Full Text
View/download PDF

184. Cigarette smoke exposure accelerates AML progression in FLT3-ITD models

Author

Figueroa, Mary, primary, Ma, Huaxian, additional, Alfayez, Mansour, additional, Morales-Mantilla, Daniel Enrique, additional, Wang, Fei, additional, Lu, Yue, additional, Estecio, Marcos, additional, King, Katherine Y, additional, Kleinerman, Eugenie S., additional, Moghaddam, Seyed Javad, additional, Daver, Naval G., additional, Andreeff, Michael, additional, Konopleva, Marina Y., additional, DiNardo, Courtney D, additional, and Chandra, Joya, additional

Published
2023
Full Text
View/download PDF

185. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Author

Short, Nicholas J., primary, Muftuoglu, Muharrem, additional, Ong, Faustine, additional, Nasr, Lewis, additional, Macaron, Walid, additional, Montalban-Bravo, Guillermo, additional, Alvarado, Yesid, additional, Basyal, Mahesh, additional, Daver, Naval, additional, Dinardo, Courtney D., additional, Borthakur, Gautam, additional, Jain, Nitin, additional, Ohanian, Maro, additional, Jabbour, Elias, additional, Issa, Ghayas C., additional, Qiao, Wei, additional, Huang, Xuelin, additional, Kanagal-Shamanna, Rashmi, additional, Patel, Keyur P., additional, Bose, Prithviraj, additional, Ravandi, Farhad, additional, Delumpa, Ricardo, additional, Abramova, Regina, additional, Garcia-Manero, Guillermo, additional, Andreeff, Michael, additional, Cortes, Jorge, additional, and Kantarjian, Hagop, additional

Published
2023
Full Text
View/download PDF

186. Supplementary Figures from Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion

Author

Desai, Poonam N., primary, Wang, Bofei, primary, Fonseca, Andre, primary, Borges, Pamella, primary, Jelloul, Fatima Zahra, primary, Reville, Patrick K., primary, Lee, Eric, primary, Ly, Christopher, primary, Basi, Akshay, primary, Root, Jessica, primary, Baran, Natalia, primary, Post, Sean M., primary, Deng, Qing, primary, Sun, Hanxiao, primary, Harmanci, Arif O., primary, Burks, Jared K., primary, Gomez, Javier A., primary, DiNardo, Courtney D., primary, Daver, Naval G., primary, Alatrash, Gheath, primary, Konopleva, Marina, primary, Green, Michael R., primary, Antunes, Dinler A., primary, Futreal, Andrew, primary, Hao, Dapeng, primary, and Abbas, Hussein A., primary

Published
2023
Full Text
View/download PDF

187. Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Author

Lachowiez, Curtis A., primary, Loghavi, Sanam, primary, Zeng, Zhihong, primary, Tanaka, Tomoyuki, primary, Kim, Yi June, primary, Uryu, Hidetaka, primary, Turkalj, Sven, primary, Jakobsen, Niels Asger, primary, Luskin, Marlise R., primary, Duose, Dzifa Y., primary, Tidwell, Rebecca S.S., primary, Short, Nicholas J., primary, Borthakur, Gautam, primary, Kadia, Tapan M., primary, Masarova, Lucia, primary, Tippett, George D., primary, Bose, Prithviraj, primary, Jabbour, Elias J., primary, Ravandi, Farhad, primary, Daver, Naval G., primary, Garcia-Manero, Guillermo, primary, Kantarjian, Hagop, primary, Garcia, Jacqueline S., primary, Vyas, Paresh, primary, Takahashi, Koichi, primary, Konopleva, Marina, primary, and DiNardo, Courtney D., primary

Published
2023
Full Text
View/download PDF

188. Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Author

Lachowiez, Curtis A., primary, Loghavi, Sanam, primary, Zeng, Zhihong, primary, Tanaka, Tomoyuki, primary, Kim, Yi June, primary, Uryu, Hidetaka, primary, Turkalj, Sven, primary, Jakobsen, Niels Asger, primary, Luskin, Marlise R., primary, Duose, Dzifa Y., primary, Tidwell, Rebecca S.S., primary, Short, Nicholas J., primary, Borthakur, Gautam, primary, Kadia, Tapan M., primary, Masarova, Lucia, primary, Tippett, George D., primary, Bose, Prithviraj, primary, Jabbour, Elias J., primary, Ravandi, Farhad, primary, Daver, Naval G., primary, Garcia-Manero, Guillermo, primary, Kantarjian, Hagop, primary, Garcia, Jacqueline S., primary, Vyas, Paresh, primary, Takahashi, Koichi, primary, Konopleva, Marina, primary, and DiNardo, Courtney D., primary

Published
2023
Full Text
View/download PDF

189. Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Author

Lachowiez, Curtis A., primary, Loghavi, Sanam, primary, Zeng, Zhihong, primary, Tanaka, Tomoyuki, primary, Kim, Yi June, primary, Uryu, Hidetaka, primary, Turkalj, Sven, primary, Jakobsen, Niels Asger, primary, Luskin, Marlise R., primary, Duose, Dzifa Y., primary, Tidwell, Rebecca S.S., primary, Short, Nicholas J., primary, Borthakur, Gautam, primary, Kadia, Tapan M., primary, Masarova, Lucia, primary, Tippett, George D., primary, Bose, Prithviraj, primary, Jabbour, Elias J., primary, Ravandi, Farhad, primary, Daver, Naval G., primary, Garcia-Manero, Guillermo, primary, Kantarjian, Hagop, primary, Garcia, Jacqueline S., primary, Vyas, Paresh, primary, Takahashi, Koichi, primary, Konopleva, Marina, primary, and DiNardo, Courtney D., primary

Published
2023
Full Text
View/download PDF

191. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC)

Author

DiNardo, Courtney D., Bannon, Sarah A., Routbort, Mark, Franklin, Anna, Mork, Maureen, Armanios, Mary, Mace, Emily M., Orange, Jordan S., Jeff-Eke, Meselle, Churpek, Jane E., Takahashi, Koichi, Jorgensen, Jeffrey L., Garcia-Manero, Guillermo, Kornblau, Steve, Bertuch, Alison, Cheung, Hannah, Bhalla, Kapil, Futreal, Andrew, Godley, Lucy A., and Patel, Keyur P.

Published
2016
Full Text
View/download PDF

192. Differentiation syndrome associated with treatment with IDH2inhibitor enasidenib: pooled analysis from clinical trials

Author

Montesinos, Pau, Fathi, Amir T., de Botton, Stéphane, Stein, Eytan M., Zeidan, Amer M., Zhu, Yue, Prebet, Thomas, Vigil, Carlos E., Bluemmert, Iryna, Yu, Xin, and DiNardo, Courtney D.

Abstract

•Enasidenib treatment may be associated with DS in patients with AML, yet diagnosis of DS is challenging because of nonspecific symptoms.•IDH inhibition-associated DS is manageable by identifying risk factors, recognizing symptoms, and initiating treatment in a timely manner.

Published
2024
Full Text
View/download PDF

194. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1

Author

Fiskus, Warren; https://orcid.org/0000-0002-7343-6214, Mill, Christopher P; https://orcid.org/0000-0003-0957-6009, Birdwell, Christine, Davis, John A, Das, Kaberi, Boettcher, Steffen; https://orcid.org/0000-0001-9937-0957, Kadia, Tapan M; https://orcid.org/0000-0002-9892-9832, DiNardo, Courtney D; https://orcid.org/0000-0001-9003-0390, Takahashi, Koichi; https://orcid.org/0000-0002-8027-9659, Loghavi, Sanam; https://orcid.org/0000-0001-8980-3202, Soth, Michael J, Heffernan, Tim, McGeehan, Gerard M, Ruan, Xinjia, Su, Xiaoping, Vakoc, Christopher R, Daver, Naval; https://orcid.org/0000-0001-7103-373X, Bhalla, Kapil N; https://orcid.org/0000-0001-5209-5126, Fiskus, Warren; https://orcid.org/0000-0002-7343-6214, Mill, Christopher P; https://orcid.org/0000-0003-0957-6009, Birdwell, Christine, Davis, John A, Das, Kaberi, Boettcher, Steffen; https://orcid.org/0000-0001-9937-0957, Kadia, Tapan M; https://orcid.org/0000-0002-9892-9832, DiNardo, Courtney D; https://orcid.org/0000-0001-9003-0390, Takahashi, Koichi; https://orcid.org/0000-0002-8027-9659, Loghavi, Sanam; https://orcid.org/0000-0001-8980-3202, Soth, Michael J, Heffernan, Tim, McGeehan, Gerard M, Ruan, Xinjia, Su, Xiaoping, Vakoc, Christopher R, Daver, Naval; https://orcid.org/0000-0001-7103-373X, and Bhalla, Kapil N; https://orcid.org/0000-0001-5209-5126

Abstract

Monotherapy with Menin inhibitor (MI), e.g., SNDX-5613, induces clinical remissions in patients with relapsed/refractory AML harboring MLL1-r or mtNPM1, but most patients either fail to respond or eventually relapse. Utilizing single-cell RNA-Seq, ChiP-Seq, ATAC-Seq, RNA-Seq, RPPA, and mass cytometry (CyTOF) analyses, present pre-clinical studies elucidate gene-expression correlates of MI efficacy in AML cells harboring MLL1-r or mtNPM1. Notably, MI-mediated genome-wide, concordant, log2 fold-perturbations in ATAC-Seq and RNA-Seq peaks were observed at the loci of MLL-FP target genes, with upregulation of mRNAs associated with AML differentiation. MI treatment also reduced the number of AML cells expressing the stem/progenitor cell signature. A protein domain-focused CRISPR-Cas9 screen in MLL1-r AML cells identified targetable co-dependencies with MI treatment, including BRD4, EP300, MOZ and KDM1A. Consistent with this, in vitro co-treatment with MI and BET, MOZ, LSD1 or CBP/p300 inhibitor induced synergistic loss of viability of AML cells with MLL1-r or mtNPM1. Co-treatment with MI and BET or CBP/p300 inhibitor also exerted significantly superior in vivo efficacy in xenograft models of AML with MLL1-r. These findings highlight novel, MI-based combinations that could prevent escape of AML stem/progenitor cells following MI monotherapy, which is responsible for therapy-refractory AML relapse.

Published
2023

195. Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion

Author

Desai, Poonam N., primary, Wang, Bofei, additional, Fonseca, Andre, additional, Borges, Pamella, additional, Jelloul, Fatima Zahra., additional, Reville, Patrick K., additional, Lee, Eric, additional, Ly, Christopher, additional, Basi, Akshay, additional, Root, Jessica, additional, Baran, Natalia, additional, Post, Sean M., additional, Deng, Qing, additional, Sun, Hanxiao, additional, Harmanci, Arif O., additional, Burks, Jared K., additional, Gomez, Javier A., additional, DiNardo, Courtney D., additional, Daver, Naval G., additional, Alatrash, Gheath, additional, Konopleva, Marina, additional, Green, Michael R., additional, Antunes, Dinler A., additional, Futreal, Andrew, additional, Hao, Dapeng, additional, and Abbas, Hussein A., additional

Published
2023
Full Text
View/download PDF

196. DDX41mutations in patients with non‐myeloid hematologic neoplasms

Author

Jelloul, Fatima Zahra, primary, Routbort, Mark. J., additional, DiNardo, Courtney D., additional, Bueso‐Ramos, Carlos E., additional, Kanagal‐Shamanna, Rashmi, additional, Thakral, Beenu, additional, Zuo, Zhuang, additional, Yin, C. Cameron, additional, Loghavi, Sanam, additional, Ok, Chi Young., additional, Wang, Sa A., additional, Tang, Zhenya, additional, You, M. James, additional, Patel, Keyur P., additional, Medeiros, L. Jeffrey, additional, and Quesada, Andrés E., additional

Published
2023
Full Text
View/download PDF

198. Abstract A50: Distinguishing Mosaic Li Fraumeni Syndrome, Clonal Hematopoiesis and Incidental Myeloid Neoplasms in Patients with Solid Tumors with Pathogenic TP53 Mutations Identified by Germline Testing or Cell-Free Circulating DNA Sequencing

Author

Loghavi, Sanam, primary, Gerstein, Yoheved, additional, Routbort, Mark J, additional, Patel, Keyur P, additional, Takahashi, Koichi, additional, Daniels, Molly, additional, Moskowitz, Julie, additional, Hammond, Danielle E, additional, Chien, Kelly, additional, Medeiros, L. Jeffrey, additional, Ravandi, Farhad, additional, Kantarjian, Hagop M, additional, Garcia-Manero, Guillermo, additional, Arun, Banu, additional, Khoury, Joseph D, additional, and DiNardo, Courtney D, additional

Published
2023
Full Text
View/download PDF

199. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Author

Lachowiez, Curtis A., primary, Loghavi, Sanam, additional, Zeng, Zhihong, additional, Tanaka, Tomoyuki, additional, Kim, Yi June, additional, Uryu, Hidetaka, additional, Turkalj, Sven, additional, Jakobsen, Niels Asger, additional, Luskin, Marlise R., additional, Duose, Dzifa Y., additional, Tidwell, Rebecca S S., additional, Short, Nicholas J., additional, Borthakur, Gautam, additional, Kadia, Tapan M., additional, Masarova, Lucia, additional, Tippett, George D., additional, Bose, Prithviraj, additional, Jabbour, Elias J., additional, Ravandi, Farhad, additional, Daver, Naval G., additional, Garcia-Manero, Guillermo, additional, Kantarjian, Hagop, additional, Garcia, Jacqueline S., additional, Vyas, Paresh, additional, Takahashi, Koichi, additional, Konopleva, Marina, additional, and DiNardo, Courtney D., additional

Published
2023
Full Text
View/download PDF

200. Abstract CT026: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies

Author

DiNardo, Courtney D., primary, Montesinos, Pau, additional, Benajiba, Lina, additional, Triguero, Ana, additional, Recher, Christian, additional, Schuh, Andre C., additional, Heiblig, Maël, additional, Bajel, Ashish, additional, Pigneux, Arnaud, additional, Alonso-Domiguez, Juan M., additional, Fathi, Amir T., additional, Grove, Carolyn, additional, Hou, Hsin-An, additional, Heuser, Michael, additional, Assouline, Sarit, additional, Fleming, Shaun, additional, Shin, Dong-Yeop, additional, Sweet, Kendra, additional, Odenike, Olatoyosi, additional, Altman, Jessica, additional, Ooi, Melissa Gaik Ming, additional, Zhentang, Lao, additional, Vey, Nobert, additional, Zeidner, Joshua, additional, Salhotra, Amandeep, additional, Wang, Eunice, additional, Schiller, Gary, additional, Porkka, Kimmo, additional, Zuckerman, Tsila, additional, Havelange, Violaine, additional, Jonas, Brian A., additional, Narayanan, Sujaatha, additional, Jang, Jun Ho, additional, Lee, Je-Hwan, additional, Szpurka, Anna M., additional, Heirich, Dana, additional, Chen, Hsiao Rong, additional, Hanft, Violet, additional, Zhao, Junjie, additional, Gueorguieva, Ivelina, additional, Zhang, Yin, additional, and Stein, Eytan M., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results